Disease · MONDO_0010434
Comparisons in its trials17
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 17 of 17
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| CMB305 (Sequentially Administered LV305 and G305)+Atezolizumab vs Atezolizumab: deaths from any cause | 31 of 45 | 27 of 44 | 89 | NCT02609984 | Trial comparisons |
| CMB305 (Sequentially Administered LV305 and G305)+Atezolizumab vs Atezolizumab: Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE) | 6 of 45 | 6 of 43 | 88 | NCT02609984 | Trial comparisons |
| CMB305 (Sequentially Administered LV305 and G305)+Atezolizumab vs Atezolizumab: Number of Participants Who Experienced At Least One Adverse Event (AE) | 44 of 45 | 43 of 43 | 88 | NCT02609984 | Trial comparisons |
| CMB305 (Sequentially Administered LV305 and G305)+Atezolizumab vs Atezolizumab: serious adverse events | 17 of 45 | 9 of 43 | 88 | NCT02609984 | Trial comparisons |
| CMB305 (Sequentially Administered LV305 and G305)+Atezolizumab vs Atezolizumab: Number of Participants Positive for Anti-New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1) Antibody at Baseline | 14 of 35 | 6 of 29 | 64 | NCT02609984 | Trial comparisons |
CMB305 (Sequentially Administered LV305 and G305)+Atezolizumab vs Atezolizumab: Number of Participants Positive for Anti-New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1) Antibody After Induction With Treatment | 16 of 32 | 0 of 27 | 59 | NCT02609984 | Trial comparisons |
| CMB305 (Sequentially Administered LV305 and G305)+Atezolizumab vs Atezolizumab: Number of Participants Positive for Anti-New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1) T Cells at Baseline | 17 of 27 | 12 of 24 | 51 | NCT02609984 | Trial comparisons |
CMB305 (Sequentially Administered LV305 and G305)+Atezolizumab vs Atezolizumab: Number of Participants Positive for Anti-New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1) T Cells After Induction With Treatment | 14 of 26 | 3 of 20 | 46 | NCT02609984 | Trial comparisons |
| Group I (Pembrolizumab, Interferon Gamma-1b) vs Group II (Pembrolizumab, Interferon Gamma-1b): Overall Response Rate (ORR) | 6 of 16 | 0 of 12 | 28 | NCT03063632 | Trial comparisons |
| Group I (Pembrolizumab, Interferon Gamma-1b) vs Group II (Pembrolizumab, Interferon Gamma-1b): Incidence of Adverse Events | 15 of 16 | 12 of 12 | 28 | NCT03063632 | Trial comparisons |
| Group I (Pembrolizumab, Interferon Gamma-1b) vs Group II (Pembrolizumab, Interferon Gamma-1b): deaths from any cause | 4 of 16 | 6 of 12 | 28 | NCT03063632 | Trial comparisons |
| Group I (Pembrolizumab, Interferon Gamma-1b) vs Group II (Pembrolizumab, Interferon Gamma-1b): serious adverse events | 4 of 16 | 5 of 12 | 28 | NCT03063632 | Trial comparisons |
| Ramucirumab + Gemcitabine + Docetaxel vs Gemcitabine + Docetaxel: deaths from any cause | 8 of 16 | 4 of 6 | 22 | NCT04145700 | Trial comparisons |
| Ramucirumab + Gemcitabine + Docetaxel vs Gemcitabine + Docetaxel: serious adverse events | 8 of 16 | 2 of 6 | 22 | NCT04145700 | Trial comparisons |
| Arm 1-Treatment (Everolimus and Imatinib Mesylate) vs Arm 2-Treatment (Everolimus and Imatinib Mesylate): serious adverse events | 2 of 12 | 1 of 2 | 14 | NCT01281865 | Trial comparisons |
| CMB305 (Sequentially Administered LV305 and G305)+Atezolizumab vs Atezolizumab: Number of Participants Experiencing a Dose-Limiting Toxicity (DLT) | 1 of 6 | 1 of 6 | 12 | NCT02609984 | Trial comparisons |
| Ramucirumab + Gemcitabine + Docetaxel vs Gemcitabine + Docetaxel: Number of Participants With Treatment-Emergent Anti-Drug Antibodies (TE-ADA) | 0 of 7 | 0 of 1 | 8 | NCT04145700 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0010434/comparisons